Authors: S.V. Ivanov, V.I. Stepanenko, O.O. Bogomolets National Medical University, Kyiv
Objective
Study of the spectrum and frequency of detection of various urogenital infections in patients with inflammatory diseases of the genitourinary tract. Determining the characteristics of clinical course, clinical and microbiological effect, safety and tolerability of the drug Orcipol (tablets productionof Laboratory Baili-Creat — Verny, France; World Medicine), as well as assessment probiotic Breveluck (capsules produced by ADIFARM Ltd., Bulgaria; World Medicine) in the restoration of normal biocenosis of the body after antibiotictherapy.
Materials and methods
Under our supervision and out patient treatment were 79 patients (36 women and 43 men) between the ages of 18 and 45 years (average age (31 ± 1.5) years) with various inflammatory diseases of the genitourinary tract caused by mixed urogenital infections.
Results and discussion
In the bacteriological method of the study, data were obtained indicating the frequent presence of anaerobic and aerobic pathogens in associations with chlamydia, mycoplasma and trichomonade infections. So, Staphylococcus epidermidismetin 63 (79.8 %) patients, S. haemolyticus — 13 (16.5 %), Streptococcus spp. — 51 (64.6 %), Staphylococcus aureus — 34 (43.1 %), Corynebacterium spp. — 19 (24.1 %), Proteus mirabilis — in 16 (20.3 %). In all cases, patients under observation have various associations of STIs and/or conditionally pathogenic flora in clinically significant credits (more than 104 COE/ml) have been registered.
Conclusions
According to studies, the combined antibacterial drug Orcipol (ciprofloxacin + ornidazole) in combination with the probiotic Breveluck in mixed infections of the genitourinary tract is a rational and effective treatment. The advantages of the chosen drug are a wide range of anti-motor effects, the ability to affect atypical pathogens and the simplest, as well as the presence of a post-antibiotic effect. High clinical efficiency, good tolerability and low frequency of development of side effects make it possible to use the drug in outpatient conditions in short courses. All presented patients with lesions of different combinations of mixed genitourinary infection achieved a clinical recovery. The high elimination rate of pathogens (93.5 %) achieved with the use of Orcipol, and a significant complacity allow to recommend this drug for the treatment of mixed urogenital tract infections. The prescribing of the probiotic Breveluck, effective for the prevention and treatment of dysbacteriosis, is also rational.
Key words: STIs (chlamydia, trichomoniasis, mycoplasmosis, ureaplasmosis), dysbiosis, examination and treatment of patients, Orcipol, Breveluck.